keyword
MENU ▼
Read by QxMD icon Read
search

Cost Anticancer drugs

keyword
https://www.readbyqxmd.com/read/28202521/ex-vivo-explant-cultures-of-non-small-cell-lung-carcinoma-enable-evaluation-of-primary-tumor-responses-to-anticancer-therapy
#1
Ellie Karekla, Wen-Jing Liao, Barry Sharp, John Pugh, Helen Reid, John Pc Le Quesne, David Moore, Catrin A Pritchard, Marion MacFarlane, J Howard Pringle
To improve treatment outcomes in non-small cell lung cancer (NSCLC), preclinical models that can better predict individual patient response to novel therapies are urgently needed. Using freshly resected tumor tissue, we describe an optimized ex vivo explant culture model that enables concurrent evaluation of NSCLC response to therapy while maintaining the tumor microenvironment. We found that ~70% of primary NSCLC specimens were amenable to explant culture with tissue integrity intact for up to 72 hours after explant...
February 15, 2017: Cancer Research
https://www.readbyqxmd.com/read/28199863/analysis-of-chemopredictive-assay-for-targeting-cancer-stem-cells-in-glioblastoma-patients
#2
Candace M Howard, Jagan Valluri, Anthony Alberico, Terrence Julien, Rida Mazagri, Robert Marsh, Hoyt Alastair, Antonio Cortese, Michael Griswold, Wanmei Wang, Krista Denning, Linda Brown, Pier Paolo Claudio
INTRODUCTION: The prognosis of glioblastoma (GBM) treated with standard-of-care maximal surgical resection and concurrent adjuvant temozolomide (TMZ)/radiotherapy remains very poor (less than 15 months). GBMs have been found to contain a small population of cancer stem cells (CSCs) that contribute to tumor propagation, maintenance, and treatment resistance. The highly invasive nature of high-grade gliomas and their inherent resistance to therapy lead to very high rates of recurrence. For these reasons, not all patients with similar diagnoses respond to the same chemotherapy, schedule, or dose...
February 12, 2017: Translational Oncology
https://www.readbyqxmd.com/read/28183252/pharmacological-profile-and-pharmacogenomics-of-anti-cancer-drugs-used-for-targeted-therapy
#3
Raffaele Di Francia, Angela De Monaco, Mariangela Saggese, Giancarla Iaccarino, Stefania Crisci, Ferdinando Frigeri, Rosaria De Filippi, Massimiliano Berretta, Antonio Pinto
Drugs for targeted therapies are primarily Small Molecules Inhibitors (SMIs), monoclonal antibodies (mAbs), interfering RNA molecules and microRNA. The use of these new agents generates a multifaceted step in the pharmacokinetics (PK) of these drugs. Individual PK variability is often large, and unpredictability observed in the response to the pharmacogenetic profile of the patient (e.g. cytochome P450 enzyme), patient characteristics such as adherence to treatment and environmental factors. Objective This review aims to overview the latest anticancer drugs eligible for targeted therapies and the most recent finding in pharmacogenomics related to toxicity/resistance because either individual gene polymorphisms or acquired mutation in a cancer cell...
February 8, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28182734/how-to-use-a-chemotherapeutic-agent-when-resistance-to-it-threatens-the-patient
#4
Elsa Hansen, Robert J Woods, Andrew F Read
When resistance to anticancer or antimicrobial drugs evolves in a patient, highly effective chemotherapy can fail, threatening patient health and lifespan. Standard practice is to treat aggressively, effectively eliminating drug-sensitive target cells as quickly as possible. This prevents sensitive cells from acquiring resistance de novo but also eliminates populations that can competitively suppress resistant populations. Here we analyse that evolutionary trade-off and consider recent suggestions that treatment regimens aimed at containing rather than eliminating tumours or infections might more effectively delay the emergence of resistance...
February 2017: PLoS Biology
https://www.readbyqxmd.com/read/28164359/off-label-drug-use-in-oncology-a-systematic-review-of-literature
#5
REVIEW
M M Saiyed, P S Ong, L Chew
WHAT IS KNOWN AND OBJECTIVE: The off-label use of medicines is widespread in several diseases. This type of prescribing practice is particularly more acute in oncology. However, the suitability of anticancer medications for off-label use remains an issue of controversy, due to uncertainty around the clinical benefits and potential toxicities, limited evidence to support clinical decision-making, increased out-of-pocket costs for patients and ethical concerns around the lack of informed consent...
February 5, 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/28158308/inefficiencies-and-patient-burdens-in-the-development-of-the-targeted-cancer-drug-sorafenib-a-systematic-review
#6
James Mattina, Benjamin Carlisle, Yasmina Hachem, Dean Fergusson, Jonathan Kimmelman
Failure in cancer drug development exacts heavy burdens on patients and research systems. To investigate inefficiencies and burdens in targeted drug development in cancer, we conducted a systematic review of all prelicensure trials for the anticancer drug, sorafenib (Bayer/Onyx Pharmaceuticals). We searched Embase and MEDLINE databases on October 14, 2014, for prelicensure clinical trials testing sorafenib against cancers. We measured risk by serious adverse event rates, benefit by objective response rates and survival, and trial success by prespecified primary endpoint attainment with acceptable toxicity...
February 2017: PLoS Biology
https://www.readbyqxmd.com/read/28152907/developing-and-implementing-emr-functionality-to-improve-oral-chemotherapy-outcomes
#7
Bruce Brockstein, George W Carro, Ashton Marie Hullett, Brad Hughes, Wayne Spath, Sharon Huginnie
: 159 Background: Approval of new oral anticancer agents (OAA) continues to rise, accounting for 75% of new oncology drugs approved so far in 2015. OAA prescriptions generated at our institution demonstrate similar growth, as the prescription volume for OAA is approximately 200% greater than it was 8 years ago. Challenges of OAA, including safe prescribing, monitoring toxicities, and assessing adherence, continue to be an obstacle to providing quality care. In recognition of these challenges, our institution employed the electronic medical record (EMR) to develop tools to enhance safe prescribing, monitoring, and follow up for patients receiving OAA...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28146116/cisplatin-oxaliplatin-and-kiteplatin-subcellular-effects-compared-in-a-plant-model
#8
Paride Papadia, Fabrizio Barozzi, James D Hoeschele, Gabriella Piro, Nicola Margiotta, Gian-Pietro Di Sansebastiano
The immediate visual comparison of platinum chemotherapeutics' effects in eukaryotic cells using accessible plant models of transgenic Arabidopsis thaliana is reported. The leading anticancer drug cisplatin, a third generation drug used for colon cancer, oxaliplatin and kiteplatin, promising Pt-based anticancer drugs effective against resistant lines, were administered to transgenic A. thaliana plants monitoring their effects on cells from different tissues. The transgenic plants' cell cytoskeletons were labelled by the green fluorescent protein (GFP)-tagged microtubule-protein TUA6 (TUA6-GFP), while the vacuolar organization was evidenced by two soluble chimerical GFPs (GFPChi and AleuGFP) and one transmembrane GFP-tagged tonoplast intrinsic protein 1-1 (TIP1...
January 31, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28141932/an-expanded-portfolio-of-survival-metrics-for-assessing-anticancer-agents
#9
Jennifer Karweit, Srividya Kotapati, Samuel Wagner, James W Shaw, Steffan W Wolfe, Amy P Abernethy
OBJECTIVES: With the introduction of more effective anticancer agents that prolong survival, there is a need for new methods to define the clinical value of treatments. The objective of this preliminary qualitative and quantitative analysis was to assess the utility of an expanded portfolio of survival metrics to differentiate the value of anticancer agents. STUDY DESIGN: A literature review was conducted of phase 3 trial data, reported in regulatory submissions within the last 10 years of agents for 6 metastatic cancers (breast cancer, colorectal cancer [CRC], melanoma, non-small cell lung cancer [NSCLC], prostate cancer [PC], and renal cell cancer [RCC])...
January 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/28125363/evaluation-of-the-asco-value-framework-for-anticancer-drugs-at-an-academic-medical-center
#10
Leslie Wilson, Tracy Lin, Ling Wang, Tanuja Patel, Denise Tran, Sarah Kim, Katie Dacey, Courtney Yuen, Lisa Kroon, Bret Brodowy, Kevin Rodondi
BACKGROUND: Anticancer drug prices have increased by an average of 12% each year from 1996 to 2014. A major concern is that the increasing cost and responsibility of evaluating treatment options are being shifted to patients. This research compared 2 value-based pricing models that were being considered for use at the University of California, San Francisco (UCSF) Medical Center to address the growing burden of high-cost cancer drugs while improving patient-centered care. PROGRAM DESCRIPTION: The Medication Outcomes Center (MOC) in the Department of Clinical Pharmacy, University of California, San Francisco (UCSF), School of Pharmacy focuses on assessing the value of medication-related health care interventions and disseminating findings to the UCSF Medical Center...
February 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28118130/development-of-a-terbium-sensitized-fluorescence-method-for-analysis-of-silibinin
#11
Saba Ershadi, Abolghasem Jouyban, Ommoleila Molavi, Ali Shayanfar
Silibinin is a natural flavonoid with potent anticancer properties, as shown in both in vitro and in vivo experiments.Various methods have been used for silibinin analysis. Terbium-sensitized fluorescence methods have been widely used for the determination of drugs in pharmaceutical preparations and biological samples in recent years. The present work is aimed at providing a simple analytical method for the quantitative determination of silibinin in aqueous solutions based on the formation of a fluorescent complex with terbium ion...
December 17, 2016: Journal of AOAC International
https://www.readbyqxmd.com/read/28105869/cost-effectiveness-and-sustainability-of-breast-cancer-screening-and-new-anticancer-drugs
#12
Giorgio Mustacchi, Daniele Generali
No abstract text is available yet for this article.
January 20, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28103080/organization-of-bbmri-pl-the-polish-biobanking-network
#13
Małgorzata Witoń, Dominik Strapagiel, Joanna Gleńska-Olender, Anna Chróścicka, Katarzyna Ferdyn, Jarosław Skokowski, Leszek Kalinowski, Jakub Pawlikowski, Błażej Marciniak, Markus Pasterk, Agnieszka Matera-Witkiewicz, Łukasz Kozera
In Poland storage of human biological samples takes place at most universities and scientific institutions conducting research projects in the field of biomedicine. The First International Biobanking Conference organized by the Ministry of Science and Higher Education in 2014 shed a light on the situation of Polish biobanking infrastructures. The country has around 40 large biorepositories, which store unique biological material such as whole brains, muscle fibers from patients with rare diseases, as well as thousands of samples from patients with lifestyle diseases...
January 19, 2017: Biopreservation and Biobanking
https://www.readbyqxmd.com/read/28095170/financial-burden-for-patients-with-chronic-myeloid-leukemia-enrolled-in-medicare-part-d-taking-targeted-oral-anticancer-medications
#14
Chan Shen, Bo Zhao, Lei Liu, Ya-Chen Tina Shih
PURPOSE: The number of targeted oral anticancer medications (TOAMs) has grown rapidly in the past decade. The high cost of TOAMs raises concerns about the financial aspect of treatment, especially for patients enrolled in Medicare Part D plans because of the coverage gap. METHODS: We identified patients with chronic myeloid leukemia (CML) who were new TOAM users from the SEER registry data linked with Medicare Part D data, from years 2007 to 2012. We followed these patients throughout the calendar year when they started taking the TOAMs and examined their out-of-pocket (OOP) payments and gross drug costs, taking into account their benefit phase, plan type, and cost share group...
January 17, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28088073/strategies-to-design-clinical-studies-to-identify-predictive-biomarkers-in-cancer-research
#15
REVIEW
Jose Luis Perez-Gracia, Miguel F Sanmamed, Ana Bosch, Ana Patiño-Garcia, Kurt A Schalper, Victor Segura, Joaquim Bellmunt, Josep Tabernero, Christopher J Sweeney, Toni K Choueiri, Miguel Martín, Juan Pablo Fusco, Maria Esperanza Rodriguez-Ruiz, Alfonso Calvo, Celia Prior, Luis Paz-Ares, Ruben Pio, Enrique Gonzalez-Billalabeitia, Alvaro Gonzalez Hernandez, David Páez, Jose María Piulats, Alfonso Gurpide, Mapi Andueza, Guillermo de Velasco, Roberto Pazo, Enrique Grande, Pilar Nicolas, Francisco Abad-Santos, Jesus Garcia-Donas, Daniel Castellano, María J Pajares, Cristina Suarez, Ramon Colomer, Luis M Montuenga, Ignacio Melero
The discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs remains one of the key challenges in cancer research. Despite its relevance, no efficient study designs to identify promising candidate biomarkers have been established. This has led to the proliferation of a myriad of exploratory studies using dissimilar strategies, most of which fail to identify any promising targets and are seldom validated. The lack of a proper methodology also determines that many anti-cancer drugs are developed below their potential, due to failure to identify predictive biomarkers...
February 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28078340/biocompatible-cus-based-nanoplatforms-for-efficient-photothermal-therapy-and-chemotherapy-in-vivo
#16
Shuwen Peng, Yuanyuan He, Murat Er, Yuanzhi Sheng, Yueqing Gu, Haiyan Chen
Near-infrared (NIR) photothermal therapy (PTT) is a new approach to ablate cancer without affecting normal tissues. A pivotal concern of PPT is to develop photo-responsive agents with high biocompatibility as well as effective photothermal conversion efficiency. Copper sulfide (CuS) nanoparticles prepared are characterized by their low synthesis cost, wide NIR absorption range, good biocompatibility and favorable NIR photothermal conversion efficiency. CuS nanoparticles were then coated with mesoporous silicon dioxide (SiO2) by the Stober method, and further loaded with anticancer drug doxorubicin (DOX)...
January 12, 2017: Biomaterials Science
https://www.readbyqxmd.com/read/28057183/immunoth%C3%A3-rapie-une-innovation-de-rupture-non-soutenable-%C3%A3-conomiquement
#17
Jean-Pierre Thierry
A NON-SUSTAINABLE BREAKTHROUGH?: The arrival of new immunotherapy anticancer drugs on the market marks a turning point. Their reference prices are fixed in the US and are positioned at the same level that the anticancer targeted therapies. They benefit from an accelerated approval process and often obtain the status of orphan drugs. The extensions of indications to many cancers and the likely combinations could significantly increase healthcare spending at a level that recently unveiled their non-sustainability, due to unrealistic prices approved by regulators...
November 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/28025935/developmental-phases-of-anticancer-screening-models
#18
Khaldoon Alsamman, Omar S El-Masry
The development of new screening models for cancer therapy is indispensable for the improvement of cancer treatment, and for the creation of alternative possibilities in the field of chemotherapy. Screening models are routinely used to reduce the cost and resources involved in anticancer drug development. The value of any screening model will ultimately be ascertained by its ability to reliably predict the clinical response. Traditional in vivo screening models have been replaced with cell-based screening assays, and these cell-based models are under constant development to better mimic in vivo conditions...
December 26, 2016: Combinatorial Chemistry & High Throughput Screening
https://www.readbyqxmd.com/read/28025934/drug-repurposing-in-anticancer-reagent-development
#19
Peng-Chen Chen, Xaiolong Liu, Yao Lin
The development process for cancer drugs is risky, lengthy and costly. Exploration of the anticancer potential of listed non-cancer drugs has become a popular research field in the pharmaceutical industry. The efficacy of various drugs are tested in multiple cancer types and the mechanisms underlying their effect were investigated. In this review, we have summarized the drug relocation instances for different cancer types in recent years and discussed the future direction of drug repurposing.
December 26, 2016: Combinatorial Chemistry & High Throughput Screening
https://www.readbyqxmd.com/read/27998104/ppy-mil-100-nanoparticles-as-a-ph-and-near-ir-irradiation-responsive-drug-carrier-for-simultaneous-photothermal-therapy-and-chemotherapy-of-cancer-cells
#20
Yu-Da Zhu, Su-Ping Chen, Huan Zhao, You Yang, Xiao-Qin Chen, Jing Sun, Hong-Song Fan, Xing-Dong Zhang
A medical nanoplatform with small size, low cost, biocompatibility, good biodegradability, and, in particular, multifunctionality has attracted much attention in the exploration of novel therapeutic methodologies. As an emerging material of self-assembled porous structure, metal-organic frameworks (MOFs) have high expectations because of their special properties compared to traditional porous materials. Therefore, integration of MOFs and functional materials is leading to the creation of new multifunctional composites/hybrids...
December 21, 2016: ACS Applied Materials & Interfaces
keyword
keyword
35915
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"